The efficacy and effectiveness of drugs for diabetes: How do clinical trials and the real world compare?

Diabetologia

Volumn 57, Issue 7, 2014, Pages 1273-1275

  Pratley, Richard E ^a,b,c  

^a FLORIDA HOSPITAL   (United States)

^b Translational Research Institute for Metabolism and Diabetes   (United States)

^c BURNHAM INSTITUTE   (United States)

Author keywords

Comparative effectiveness research; DPP 4 inhibitor; Drug efficacy; Observational study; Randomised controlled trial; Sulfonylurea; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA; VILDAGLIPTIN;

CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DIABETES CONTROL; DIABETES MELLITUS; DRUG EFFICACY; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; TREATMENT OUTCOME;

EID: 84903435739     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3263-3     Document Type: Note

References (3)

1. DeMets DL, Califf RM (2011) A historical perspective on clinical trials innovation and leadership. Where have the academics gone? JAMA 305:713-714
2. Ahrén B, Mathieu C, Bader G, Schweizer A, Foley JE (2014) Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational trials. Diabetologia. doi:10.1007/s00125-014-3222-z
3. Mathieu C, Barnett AH, Brath H et al (2013) Effectiveness and tolerability of second-line therapy with vildagliptin vs other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract 67:947-956